awmsg logo



aripiprazole monohydrate (Abilify Maintena®)


Reference No. 909

Publication date:
14/08/2014


Appraisal information

aripiprazole monohydrate (Abilify Maintena®) 400 mg powder and solvent for prolonged-release suspension for injection


Company: Otsuka Pharmaceutical (UK) Ltd
BNF category: Central nervous system
NMG meeting date: 18/06/2014
AWMSG meeting date: 16/07/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2214
Ministerial ratification: 13/08/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Aripiprazole (Abilify Maintena®) 400 mg powder and solvent for prolonged released suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download